key: cord-1019235-qp0ferbq
authors: Ramos, Michael S.; Xu, Lucy T.; Singuri, Srinidhi; Castillo Tafur, Julio C.; Arepalli, Sruthi; Ehlers, Justis P.; Kaiser, Peter K.; Singh, Rishi P.; Rachitskaya, Aleksandra V.; Srivastava, Sunil K.; Sears, Jonathan E.; Schachat, Andrew P.; Babiuch, Amy S.; Sharma, Sumit; Martin, Daniel F.; Lowder, Careen Y.; Singh, Arun D.; Yuan, Alex; Nowacki, Amy S.
title: Patient-reported complications after intravitreal injection and their predictive factors
date: 2020-10-12
journal: Ophthalmol Retina
DOI: 10.1016/j.oret.2020.09.024
sha: ebbab10f776ec8b185339dd84d7f4478a244a95d
doc_id: 1019235
cord_uid: qp0ferbq

OBJECTIVE: The intravitreal injection (IVI) of pharmacological agents is the most commonly performed ocular procedure and is associated with a host of complications. The majority of IVI-related complications data is derived from randomized controlled clinical trials, which report a high adverse event rate. The nature of these protocol-driven trials limit their applicability to the diverse circumstances seen in routine clinical practice. The goal of this study is to determine the prevalence of patient reported IVI-related complications, their risk factors, and the manner in which patients presented in a tertiary eye care center. DESIGN: A retrospective, IRB-approved review. SUBJECTS, PARTICIPANTS AND/OR CONTROLS: 44,734 injections in 5,318 unique patients at the Cleveland Clinic Cole Eye Institute from 2012-2016. METHODS, INTERVENTION, OR TESTING: Intravitreal injection. MAIN OUTCOME MEASURES: Complication occurrence within 15 days of injection. RESULTS: From 2012-2016, a total of 44,734 injections were performed in 5,318 unique patients. Overall, complication rates were low, representing 1.9% of all injections, with 1031 unique complications in 685 (12.9%) patients. The most common minor complications, or those not requiring intervention, were irritation (n=312) and subconjunctival hemorrhage (n=284). The most common serious complications, or those requiring intervention, were corneal abrasion (n=46) and iritis (n=31). The majority of complications (66%) were adequately managed by a telephone/Epic electronic message encounter only. Importantly, no injection protocol parameter, such as type of anesthesia, preparation, or post-injection medication, increased the risk of a complication. However, patient sex, age, number of previous injections, and provider strongly influenced the risk of patient-reported complications. CONCLUSIONS: Overall, complication rates seen in routine clinical practice were low compared to clinical trial reporting. Providers should feel confident in the safety and administration of IVI during times when follow-up office visits and resources may be limited. When performing an IVI, factors such as a patient’s sex, age, number of previous injections, and provider must be taken into account to ensure the best possible outcomes.

irritation (n=312) and subconjunctival hemorrhage (n=284). The most common serious complications, or 52 those requiring intervention, were corneal abrasion (n=46) and iritis (n=31). The majority of 53 complications (66%) were adequately managed by a telephone/Epic electronic message encounter only. 54

Importantly, no injection protocol parameter, such as type of anesthesia, preparation, or post-injection 55 medication, increased the risk of a complication. However, patient sex, age, number of previous 56

injections, and provider strongly influenced the risk of patient-reported complications. 57

Conclusions: Overall, complication rates seen in routine clinical practice were low compared to clinical 58 trial reporting. Providers should feel confident in the safety and administration of IVI during times when 59

follow-up office visits and resources may be limited. When performing an IVI, factors such as a patient's 60 sex, age, number of previous injections, and provider must be taken into account to ensure the best 61 possible outcomes. 62 63 64

Recent decades have seen a dramatic increase in the number of intravitreal injections (IVI) 71 performed worldwide. 1 The increasing popularity of intravitreal therapeutics among providers has made 72 IVI the most common intraocular procedure, with an estimated 6 million performed annually in the US as 73 of 2016. 1 While the administration of intravitreal therapeutics often helps to maintain, and even improve 74 vision, IVI is associated with a host of complications ranging from irritation to infection. 75

Most data on IVI-related complications are from randomized controlled trials (RCT), which are 76 designed with rigorous participant selection criteria, pre-determined follow-up times, and other highly 77 controlled conditions aimed at minimizing potential bias. In these protocol-driven trials, adverse event 78

reporting can reach rates as high as 74-92% of patients. 2,3 While establishing internal validity, the 79 applicability of these trials to diverse patient populations and the variable conditions found in routine 80 clinical practice may be limited. 4 For investigators desiring clinically representative data, a well-powered, 81 pragmatic design should be considered. 82

While some non-randomized controlled trial studies of IVI-related complications do exist, these 83 are often limited in scope. These types of studies have primarily focused on endophthalmitis, the biggest 84 threat to a patient's visual acuity. However, endophthalmitis is exceedingly rare with incidence ranging 85 from 0.015 -0.08% of injections. [5] [6] [7] Other studies look at individual complications such as 86 subconjunctival hemorrhage (SCH) or intraocular inflammation, with reported rates of 10% for SCH 8 and 87 0.09-2.9% for intraocular inflammation, depending on the intravitreal agent. 9 Furthermore, more recent 88 studies expand beyond specific complications and report on post-procedural pain. 10,11 These studies are 89 often limited to a few agents or a small number of total injections and fail to evaluate the collective 90 complications seen in routine clinical practice. 91

This study aims to contribute to the paucity of pragmatic research on IVI-related non-infectious 92 complications. We conducted a retrospective cohort study to determine the IVI-related complication rate 93 J o u r n a l P r e -p r o o f at a high-volume tertiary eye care center. We then describe the initial presentations of these patients to 94 better prepare providers in complication management. Finally, we identify potential risk factors 95 associated with IVI-related complications. 96

Identifying IVI-related complications 98

We identified a total of 44,734 injections of eight common intravitreal agents based on the For all study subjects, we collected baseline demographic and clinical information including sex, 117 ethnicity, age at injection, eye injected (OD, OS, or OU), intravitreal agent, number of previous 118 injections, and provider. Additionally, we collected the following clinical information for each 119 complication: type of encounter, days to presentation, and type of complication. Complications were 120 divided into three groups: minor, serious, and unrelated. Endophthalmitis cases were excluded from this 121 study; however, we identified 19 presumed endophthalmitis cases related to an IVI (Figure 1 ). This 122 observed rate of 0.042%, or 1:2355 injections was similar to published reports. 6,12,13 Minor complications 123 were those not requiring intervention or observation and included irritation, subconjunctival hemorrhage 124 (SCH), and visual disturbance from an air bubble or medication. Irritation included the following 125 complaints or pathologies: discharge, epitheliopathy, keratoconjunctivitis, punctate keratitis, punctate 126 epithelial erosions, redness, superficial keratopathy, or tearing. Serious complications were those 127 requiring either medical intervention or close observation and included complications requiring surgery 128 (e.g. retinal detachment) or intervention (e.g. retinal tear requiring laser). Very rare complications with 129 only one occurrence were grouped together under "other" in the serious group. Unrelated complications 130 included those not resulting from the IVI itself, but instead were thought to be due to disease progression. 131

These were noted based on next available ocular exam chart notes and confirmed by a trained 132

To identify potential risk factors associated with complications, the injection protocol parameters 134 including types of anesthesia, preparation, post-injection medication used, and anterior chamber 135 paracentesis were collected (Table 5) . Post-injection medications were those used in the clinic 136 immediately following injection. These did not include patient prescriptions. These parameters are 137 recorded by our electronic medical record system (Epic). (multiple injections per patient) assuming a binomial distribution and a logit link function. An 143 exchangeable correlation structure was assumed in which the observations within a patient are assumed to 144 be equally correlated. Each model included one injection protocol factor and adjusted for patient sex, 145 ethnicity, age, whether or not same day bilateral injection, provider and number of visits in sample. When 146 a zero cell was encountered, it was imputed with a one to avoid division by zero. This analysis was 147 repeated for the binary outcomes of any serious complication, irritation and subconjunctival hemorrhage. 148

A significance level of 0.05 was utilized. As this study was exploratory in nature regarding the various 149 steps of the injection protocol, we aimed to maximize the chance of detecting a signal and did not make 150 any adjustments for multiple comparisons. All data analyses were performed using SAS version 9.4 151 statistical software (SAS Institute, Cary, NC). 152

The injected study sample 154 Eye Institute. 56% of the total patient population was female, and 80% were Caucasian. Median age at 156 injection was 75.7 years (Q 1 -Q 3 , 65.1-84.2). Of the injection characteristics, OD and OS injections were 157 evenly split each with 37% of injections, while 26% of injections were same-day bilateral injections. 95% 158 of injections used an anti-VEGF agent, with the most common agent being bevacizumab (54%). The 159 median number of injections per patient across the five-year study period was 5 (range, 1-110). Injections 160 were administered by 16 unique providers with a median number of injections per provider of 2416 161 (range, 141-6027).Patient and injection characteristics can be found in Table 1 . 162

From 2012-2016, 1031 unique complications from 685 patients presented in 841 encounters. 81% 164 of these encounters had only 1 complication (Table 2 ). In 66% of encounters, the patient first presented 165 encounters, 63.4% were handled by call or Epic electronic message only, 29.2% resulted in a scheduled 167 follow-up visit, and 7.4% resulted in the patient initiating an unscheduled urgent visit following the initial 168

contact. This last patient subset included those who first presented by telephone call/Epic electronic 169 message and were told to "return as needed". These patients then initiated an unscheduled urgent office 170

visit. This patient subset represented 4.8% of total encounters and presented with only 5.5% of all 171 complications, the majority of which were minor (Table 3) . Office visits and emergency department visits 172 accounted for 32% and 2% of encounters, respectively. The majority of minor complications first 173 presented by telephone call/Epic electronic message, while a larger percentage of serious complications 174 first presented by office visit compared to telephone call/Epic electronic message (Figure 2 ). The median 175 number of days to an encounter was 2 days (Q 1 -Q 3 , 1-6). 176

Overall, the rate of any complication was 1.9% of total injections (Table 4) (Table 4 ). No single protocol parameter was associated significantly with any complication 182 (Table 5 ). The small protocol parameter effects were insignificant when compared to the large effects of 183 patient sex, number of injections performed, and provider. The odds of having any complication increased 184 for females, decreased with each additional injection, and varied greatly amongst different providers. 185

Provider complication rates ranged from 1.00 to 5.67% with the majority of providers having a rate of 186 less than 2.0%. 187

We took a closer look at complications which were represented by higher frequencies, allowing 189 us to perform a more focused investigation. These included irritation (n=312), subconjunctival 190 J o u r n a l P r e -p r o o f hemorrhage (n=284) and any serious complication (n=157). After adjusting for confounders, regression 191 analysis showed that most protocol parameters were not associated with irritation nor SCH. Receiving a 192 post-injection medication decreased the risk of irritation (Table S1 , p = 0.045), while the use of a 193 subconjunctival injection of lidocaine increased the risk of SCH (Table S2, 

When modeling the outcome of any serious complication, no associations were found with 203 injection protocol parameters. Interestingly, the sex of the patient no longer impacted risk but rather the 204 patient's age at injection played a role. Like previous analyses, the number of previous injections 205 remained a statistically significant factor. Consistently across all protocol parameters, as the patient's age 206 increased, the risk of any serious complication decreased; furthermore, as the number of injections 207 increased, the risk decreased. The provider no longer impacted the risk of any serious complication. 208

With this retrospective review, we characterize common complications seen in routine clinical 210 practice following IVI. Our analysis showed a complication rate of 1.9% of all injections, or 12.9% of all 211 patients. This rate was significantly less than clinical trial adverse event reporting, such as those in Rise, 212

Ride, View 1, and View 2 trials, which showed rates of 90.1%, 81.2%, 76%, and 62.5% of patients, 213 respectively. 2,3 These protocol-driven studies, in the quest to establishing safety and efficacy, use pre-214 determined follow-up schedules in which all adverse events are reported. These studies report 215 complication rates observed by investigators while our study looks at patient-initiated encounters 216 concerning a complication, which more closely represents what is encountered in routine clinical practice. 217

Unlike in a clinical trial, patients may not always report or even notice a complication, explaining the 218 difference between the rates observed in clinical trials and the present study. 219

The overall low rate of complications suggests a low burden on additional health care resources This study, in contrast to prior reports, included more types of serious complications and a larger 228 number of injections, lending to its application to the general population. 14-17 The overall low 229 complication rate and even lower serious complication rate should provide confidence to patients and 230 providers when discussing the safety profile of this common intervention. Providers should also be aware 231 that the majority of non-infectious complications present within 2 days of injection, while other studies 232 have shown that most infectious cases present after 2 days. 18 233

Interestingly, this study did not uncover any specific injection protocol parameters that 234 significantly increased the risk of developing any complication. Looking specifically at SCH and 235 irritation, subconjunctival anesthesia increased the risk of SCH. More surprisingly, use of post-procedural 236 medicated eye drops decreased the risk of irritation. The effect is small and, while statistically significant, 237 may have less clinical importance. However, perhaps the use of drops in the office provided a lubricating 238 effect or may serve to flush out residual betadine prep. There may be a tendency to rinse the ocular 239 surface more after using a disinfectant drop at the end of the procedure which may also ease post-240 J o u r n a l P r e -p r o o f injection irritation. It is also important to note that all providers in this study recommend the use of 241 artificial tears on an "as needed" basis following injections. The use of artificial tears by the patient could 242

have an impact on subsequent complication presentations; however, this parameter was not captured by 243 our electronic medical record system and thus not included in our analysis. 244

Our study suggests the patient's sex, number of previous injections, and provider strongly 245 impacts the risk of any complication. Females were at a 32% increased risk of complication compared to 246 men. This could point to gender differences in the use of healthcare services. 19 Psychological factors 247 could also come into play with social constructs such as masculinity. 20,21 The exact reason still needs 248

investigation, but providers should be aware that men may not as frequently present with complications as 249 compared to women. With serious complications, age at injection, rather than sex, played a role. Changes 250 in ocular anatomy or physiology could result in these differences. 22 Younger patients may have a more 251 robust inflammatory system which could account for the higher rates of inflammation following 252 injection. 23 Other explanations include older patients receiving more injections and therefore are more 253 familiar with, and less concerned with disturbances after the injection or these patients being less capable 254 of initiating a complication encounter. To this latter point, serious complications among older patients 255 could be under reported due to obstacles arranging transportation to appointments or technological 256 barriers in scheduling appointments or calling their eye care center. This underreporting may encourage 257 providers to assess their older patients' access to care and post-injection follow-up 258

Surprisingly, our analysis showed that as the number of previous injections increased, the risk of 259 a complication decreased. One possible explanation is that as the patient received more injections, influence patient encounters. Patients receiving an injection within our health system, experiencing a 279 complication, and then following up at a location outside the system is a possibility, albeit likely to 280 represent only a very small fraction of visits. Lastly, with any retrospective study, some aspects could not 281 be captured, such as lid speculum usage 1,24 and injection site; 1,25 which may or may not play a role in 282

complications. Missing data also limited the study, but the size of our study should help mitigate any 283 effects on rates. were excluded from this study. 359 J o u r n a l P r e -p r o o f 0.7% (7) Total 5.5% (57) This subset of the patient population represented those who first presented by telephone call/Epic electronic message and were told by a provider to "return as needed", after which the patient initiated an unscheduled, urgent office visit. Total complications in all encounters was 1031.

J o u r n a l P r e -p r o o f 

Update on Intravitreal Injections: Euretina Expert 294 Consensus Recommendations. Ophthalmologica

Ranibizumab for Diabetic Macular Edema: Results 296 from 2 Phase III Randomized Trials: RISE and RIDE

Intravitreal aflibercept (VEGF trap-eye) in wet age-related 299 macular degeneration

A pragmatic view on pragmatic trials

Outcomes and risk factors 303 associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth 304 factor agents

Meta-analysis of infectious endophthalmitis after intravitreal 306 injection of anti-vascular endothelial growth factor agents

Endophthalmitis after Intravitreal Injection of Vascular 309

Endothelial Growth Factor Inhibitors: Management and Visual Outcomes

Safety of repeat 312 intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. 313 Retina

Topical Nonsteroidal Anti-inflammatory Drugs for 317 Pain Resulting from Intravitreal Injections: A Meta-Analysis

Optimizing the Patient Experience and Satisfaction: The Role 320 of Topical NSAIDs with Intravitreal Injections

Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength

Pooled Estimates of Incidence of Endophthalmitis 326 after Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents with and without 327 Topical Antibiotic Prophylaxis

Short-term complications of intravitreal injections of 329 triamcinolone and bevacizumab

The incidence of serious complications associated with intravitreal 331 therapy in a quaternary ARMD service

Complications of intravitreal injection of triamcinolone acetonide

Severe corneal changes following 336 intravitreal injection of bevacizumab

Clinical 339 characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth 340 factor

Beyond the caveman: Rethinking masculinity in relation to men's help-seeking

Health (Irvine Calif)

Masculinity, and the Contexts of Help Seeking

The psychology of men's health: Maximizing masculine capital. Heal Psychol

Anatomic 348 alterations in aging and age-related diseases of the eye

Interventions to restore appropriate immune function in the elderly

Povidone-iodine contact time and lid speculum 353 use during intravitreal injection

Intravitreal injections: a review of the evidence for best practice

In routine clinical practice, the complication rate following intravitreal injection is low, representing 1.9% of all injections. Factors influencing the risk of patient-reported complications include a patient's sex, age